
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What New Prospective Research Reveals About (177Lu)Lu-PSMA-I&T for Patients with mCRPC
2
PET Radiotracer Gets FDA Breakthrough Therapy Designation for Tumor Hypoxia Detection in HPV-Positive Oropharyngeal Carcinoma
3
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 1
4
Study: Chest CT AI Software Facilitates Nearly 15 Percent Reduction in Reporting Time
5










